Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9607739 | 0.89 | TP53 (0.45) | ADORA1ADORA3ADORA2ATP53LMNA | |
| SCHEMBL9607737 | 0.85 | IRAK4 (0.42) | ADORA1ADORA3ADORA2ATP53LMNA | |
| SCHEMBL9609068 | 0.79 | BTK (0.51) | — | |
| SCHEMBL9608997 | 0.76 | TBK1 (0.45) | CNR1 | |
| SCHEMBL6920488 | 0.75 | DRD3 (0.42) | LMNAPOLB | |
| SCHEMBL22897343 | 0.75 | EGFR (0.44) | ADORA1ADORA3ADORA2ATP53LMNA | |
| SCHEMBL787083 | 0.74 | ADORA3 (0.47) | ADORA1ADORA3ADORA2ATP53LMNA | |
| SCHEMBL4823172 | 0.72 | ADORA1 (0.51) | ADORA1ADORA3ADORA2ATP53ALOX5 | |
| SCHEMBL6918294 | 0.71 | F9 (0.52) | EGFRNPC1RAB9APOLB | |
| SCHEMBL19004849 | 0.71 | HPGDS (0.44) | ADORA1ADORA3ADORA2ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | ADORA1 1224/4885ADORA3 847/4885ADORA2A 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.